 Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for mavorixafor plus ibrutinib therapy in double-mutation Waldenströms patients; meaningful increases in hemoglobin levels suggest reduction in cancer burden in bone marrow 